Hot Topics

Poll

Governments can ration access to cancer drugs, or break patent monopolies. Why is rationing so popular?:

Put the patents at risk, not the patients

The TPP, following a plethora of other trade agreements involving the United States, the European Union and Japan as trading partners, seeks to expand and extend drug monopolies, by requiring lower standards for the grant of patents, extensions of patent terms, exclusive rights in test data, among other measures. These proposals and polices are designed to have the predictable effect of making drug prices higher.

WHA68: Statement of HAI/KEI on Follow-up to 2014 HLM on comprehensive review + assessment of prevention and control of NCDs

On Tuesday, 26 May 2015, the following statement was delivered in Committee B of the 68th World Health Assembly on behalf of Stichting Health Action International and Knowledge Ecology International on the topic: Follow-up to the 2014 high-level meeting of the United Nations General Assembly to undertake a comprehensive review and assessment of the progress achieved in the prevention and control of noncommunicable diseases.

May 21, 2015- Agenda for KEI/KEI Europe panel on Compulsory licensing of patents on drugs, vaccines and diagnostic tests

Panel discussion
Compulsory licensing of patents on drugs, vaccines and diagnostic tests

Knowledge Ecology International (KEI) and Knowledge Ecology International Europe (KEI Europe):

DATE: Thursday, 21 May 2015
TIME: 17:30-19:00
VENUE: Kofi Annan Room, UNAIDS, Avenue Appia 20

Moderator:

  • Ellen 't Hoen, Medicines, Law and Policy

Panel members

WHA68: Greek Minister of Health - Panagiotis Kouroumplis - calls for de-linkage of R&D from the price of health technologies

On Monday, 18 May 2015, the Greek Minister of Health, Panagiotis Kouroumplis, delivered the following speech at the World Health Assembly in Geneva, explicitly calling for the de-linkage of the "cost of R&D from the final price of medicines" while highlighting the deleterious effects of austerity measures eroding public health systems, counter to the theme of WHA68, "Resilient Health Systems".

Here is his speech in full:

Madam Director General, dear colleagues, excellencies, ladies and gentlemen

KEI TPP Briefing note 2015:1 Compulsory licenses on patents and the 3-step test

This is a briefing note prepared for TPP negotiators, addressing a single but important issue, the standards for issuing compulsory licenses in the TPP.

Letter from Senator Bernie Sanders to the VA, asking for compulsory licenses on Hepatitis C drugs.

Attached is the text of a letter sent by Senator Bernie Sanders to Robert A. McDonald, the Secretary, U.S. Department of Veterans Affairs, asking the Secretary "to use your authority as Secretary of Veterans Affairs to break the patents on Hepatitis C medications for the treatment of veterans suffering with the disease."

UACT Comments to DHHS on WHA: Agenda Item 13.4 Assessment of Progress in Prevention & Control of NCDs

To prepare for the upcoming 68th World Health Assembly (WHA), the U.S. Department of Health & Human Services held a Stakeholder Listening Session on Friday, May 8, 2015, from 10:30am - 12pm in the HHS Humphrey Building - 200 Independence Ave, SW, Washington, DC 20201. All Agenda items for the upcoming WHA are here:
http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf

KEI Comments to DHHS on WHA Agenda 17.5 (Global Strategy and Plan of Action on Public Health, Innovation and IP)

Andy-IMG_3181_600x.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here.

KEI comments to DHHS on WHA agenda 17.4, the Consultative Expert Working Group on Research and Development

Re: 17.4 Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination Document A68/34

My name is James Love, from Knowledge Ecology International. I wanted to discuss the negotiations on new approaches to funding medical R&D.

I will begin with the much delayed discussions about a WHO R&D treaty, which are supposed to resume in 2016.

We have suggestions for some changes in the discussion, to move things forward.

KEI Comments on DHHS Session on WHA68, agenda item 14.1, regarding collection of economic data

Rajasingh-1-IMG_3157_1024x716.pngOn Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here:

KEI Comments to DHHS on WHA68 agenda 11.2, Framework of Engagement with Non-State Actors

On Friday May 8, 2015, the US Department of Health and Human Services held a listening session to solicit input on the agenda items for the upcoming 68th World Health Assembly. KEI delivered five interventions covering a range of critical WHA topics. The full provisional agenda of the 68th WHA can be accessed here: http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_1-en.pdf
jimmy-claire_1024x.png

WHO Expert Committtee adds trastuzumab, imatinib, daclatasvir, sofosbuvir, bedaquiline and delaminid to EML

On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).

With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.

WHO donors in 2014 (US, Gates Foundation, UK, GAVI and Canada): Setting the agenda for global public health?

In preparation for the 68th World Health Assembly, to be convened in Geneva from 18 May 2015 to 26 May 2015, the World Health Organization (WHO) prepared a document (A68/INF./1, 1 May 2015), entitled "Annex to the Financial Report for the year ended 31 December 2014, Voluntary contributions by fund and by contributor).

Letter from KEI to USPTO regarding implementation of Beijing Treaty

On May 5, 2015, KEI sent a letter to the USPTO regarding the implementation of the Beijing Treaty on Audiovisual Performances. The letter focuses on concerns that KEI and others have expressed that a treaty implementation by amendment of 17 U.S. Code § 1101, regarding the "Unauthorized fixation and trafficking in sound recordings and music videos," creates problems, because the statute involves a right that is perpetual and not subject to normal copyright exceptions.

NIH refuses to give information about principals in company seeking exclusive license to HCV patents

The NIH provided these responses to four questions about the HCV drug patent license it is considering.

Syndicate content